Back to discover

Protein / target

Vesicle-associated membrane protein 2

Encoded byVAMP2P63027Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
Antibody-tractable
Druggability
GO CC high conf
2
Research papers

Protein at a glance

Biological role

Calcium-dependent protein binding

Strongest disease association

Botulism

Via encoding gene VAMP2 · Pathway evidence · score 0.53

Therapeutic position

Established drug target

Research activity

Emerging research

2 papers · latest 2010

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

SNAREs (soluble N-ethylmaleimide-sensitive factor-attachment protein receptors) are essential proteins for intracellular membrane fusion.

View complete UniProt function annotation

SNAREs (soluble N-ethylmaleimide-sensitive factor-attachment protein receptors) are essential proteins for intracellular membrane fusion. SNAREs localized on opposing membranes assemble to form a trans-SNARE complex, an extended, parallel four-helix bundle whose assembly releases energy that drives membrane fusion. The core SNARE complex typically consists of four alpha-helical domains, three from target membrane SNAREs (t-SNAREs) and one from a vesicle SNARE (v-SNARE) (PubMed:10036234, PubMed:30929742). VAMP2 is a v-SNARE assembling into a SNARE complex with the t-SNAREs SNAP25 and STX1A to mediate the fusion of synaptic vesicles with the presynaptic plasma membrane in neurotransmitter release (PubMed:30929742). Also functions in compensatory endocytosis for synaptic vesicle recycling (By similarity). In adipocytes, it is involved in the insulin-dependent exocytosis of GLUT4 storage vesicles (By similarity). Independently of its SNARE activity, it could modulate the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 (By similarity)

Subcellular location

Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneCell membrane
Domains and Gene Ontology detail (53)

Domains & features

v-SNARE coiled-coil homology

Gene Ontology

  • Cclathrin-coated endocytic vesicle membrane
  • Cclathrin-coated vesicle
  • Cclathrin-sculpted gamma-aminobutyric acid transport vesicle membrane
  • Cclathrin-sculpted glutamate transport vesicle membrane
  • Cclathrin-sculpted monoamine transport vesicle membrane
  • Ccytoplasmic vesicle
  • Ccytosol
  • Cmembrane
  • Cneuron projection
  • Cneuron projection terminus
  • Cperinuclear region of cytoplasm
  • Cplasma membrane

116 aa · 13 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Synaptic signallingUniProt · GO
View supporting evidence

Synaptic signalling

  • ·SNAREs (soluble N-ethylmaleimide-sensitive factor-attachment protein receptors) are esse…
  • ·presynaptic membrane
  • ·synapse

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene VAMP2

Gene-level evidence surfaced through the gene VAMP2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Botulism
0.35Preliminary

Pathway evidence dominant · Open Targets 0.53 · no direct causal or clinical evidence

View evidence synthesis (1)
BotulismPreliminary
0.35
agreement 0.170.53
Pathway98%Literature2%

Open Targets aggregate 0.53 · 2 independent evidence families · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Botulism0.53

Drug development

1 compounds recorded · 1 approved

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (1)
RIMABOTULINUMTOXINBApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

AntibodiesEmerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Approved Drug support this modality.

View underlying tractability evidence (6)
AB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Half-life DataOC · Approved Drug

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2010

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Burré J · Science (New York, N.Y.) · 2010

Halassa MM · The Journal of neuroscience : the official journal of the Society for Neuroscience · 2007

Recent

Synaptic islands defined by the territory of a single astrocyte.

Halassa MM · The Journal of neuroscience : the official journal of the Society for Neuroscience · 2007

Europe PMC papers linked directly to this protein.